The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
Ensuring Access to Medicines for Patients: Pharmaceutical Industry Associations Release ‘Principles for Communication of Information on Quality and Manufacturing Potential Supply Disruption’ +
(20th January 2015 – Brussels) – AESGP, EFPIA, EGA, and PPTA are pleased to announce today’s release of the joint principles for “Communication of information on quality and manufacturing potential supply disruption”. This document forms part of the industry response to the EMA (European Medicines Agency) call for voluntary and proactive action, to provide European patients with continuous access to medicines.Read More
PPTA Statement on MSM Donor Policy at the Blood Products Advisory Committee Meeting on December 2, 2014 +
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies, collectively referred to as plasma protein therapies. Plasma protein therapies are used in the treatment of a number of rare diseases.Read More
International Plasma Protein Congress Registration Now Open! +
IPPC 2015 REGISTRATION is now Open!!
10-11 March 2015
Preliminary program now available.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly. Read the current issue.